Friday, April 09, 2021 4:46:31 PM
'Relief Therapeutics, a penny stock trading under RLFTF is a small Swiss biotech that owns the rights to synthetic vasoactive intestinal peptide (VIP). The substance is also known by the trademarked names, aviptadil, RLF-100 and Zyesami. VIP is a peptide.'
"OWNS the RIGHTS to RLF-100/VIP/*brand name."
It is GOOD to see mention of the 'other' CT.
'EAP CLINICAL TRIAL RESULTS:
Relief Therapeutics has enrolled more than 200 patients in their compassionate use (EAP) program. These patients were patients who were too sick for the Phase 3 trial. Patients who had multiple comorbidities such as: lung transplant patients, patients with lung cancer, patients who were immunocompromised or had evidence of severe, multisystem organ dysfunction.
Initial data from a 102 patient sample size showed a 72% rate of survival with aviptadil + SOC vs 27% SOC. Although full results of the EAP 200+ patients have not been reported to date, it is reasonable to assume that results will continue to show the same, favorable outcome.'
...GLTA...
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM